First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
Public ClinicalTrials.gov record NCT05875168. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 1/2, Open-label, Multicenter, First-in-Human Study of DS-3939a in Subjects With Advanced Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will evaluate the safety, tolerability, and efficacy of DS-3939a in participants with advanced solid tumors.
Study identification
- NCT ID
- NCT05875168
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 590 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 18, 2023 (Actual)
- Primary completion
- Aug 11, 2028 (Estimated)
- Completion
- Nov 11, 2028 (Estimated)
- Last update posted
- Oct 15, 2026
2023 – 2028
United States locations
- U.S. sites
- 12
- U.S. states
- 12
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Florida Cancer Specialists | Sarasota | Florida | 34232 | Recruiting |
| Piedmont Cancer Institute | Locust Grove | Georgia | 30248 | Withdrawn |
| University of Kansas Medical Center | Westwood | Kansas | 66205 | Recruiting |
| Henry Ford Health System | Detroit | Michigan | 48202 | Withdrawn |
| Astera Cancer Care | East Brunswick | New Jersey | 08816 | Recruiting |
| Icahn School of Medicine Mt Sinai | New York | New York | 10029 | Withdrawn |
| Oregon Health & Science University | Portland | Oregon | 97239 | Recruiting |
| Rhode Island Hospital | Providence | Rhode Island | 02903 | Recruiting |
| University of Texas M.D. Anderson Cancer Center | Houston | Texas | 77030 | Recruiting |
| Huntsman Cancer Institute, University of Utah | Salt Lake City | Utah | 84112 | Recruiting |
| Virginia Cancer Specialists | Fairfax | Virginia | 22031 | Withdrawn |
| The Medical College of Wisconsin, INC | Milwaukee | Wisconsin | 53226 | Withdrawn |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 45 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05875168, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 15, 2026 · Synced Nov 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05875168 live on ClinicalTrials.gov.